News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Cleveland Fed's Hammack says labor is near full employment and warns the Fed may raise rates if inflation keeps rising.
  • Broadcom shares fell after a mixed quarter and weaker-than-expected AI revenue guidance, deepening semiconductor-sector weakness.
  • NVIDIA slid after a stronger-than-expected jobs report raised rate concerns and amplified semiconductor headwinds.
  • Eli Lilly shares rose on Phase 3 retatrutide results and new oral GLP-1 data presented at the ADA meeting.
  • UK regulator seized control of Euro Exchange over money-laundering concerns and is seeking special administration.
  • Dilutive offerings and resale filings triggered steep selloffs at USA Rare Earth, BlockchAIn, Ocean Power, and Navitas.
  • Macron, Starmer and Merz will meet Zelenskiy in London on June 7 to coordinate additional support for Ukraine.

Latest Articles

Nexera Technologies Announces Receipt of Nasdaq Listing Approval for Majority-Owned Subsidiary Fort Technology

Nexera Technologies Announces Receipt of Nasdaq Listing Approval for Majority-Owned Subsidiary Fort Technology

Nexera Technologies Ltd announced that its majority-owned subsidiary, Fort Technology Inc., has received formal Nasdaq approval to list its common shares on the Nasdaq Capital Market under the ticker symbol "FRTT." Fort Technology's shares will continue trading on the TSX Venture Exchange. Nexera holds approximately 70.94% equity in Fort Technology…

Danone: Pivoting to Nutrition Growth Under a Dairy Valuation

Danone: Pivoting to Nutrition Growth Under a Dairy Valuation

Danone is trading near the low end of its 52-week range despite tangible progress on strategic moves: confirmed 2026 guidance, the Huel acquisition, a dairy JV in Argentina, and strengthened funding for precision fermentation partners. The stock looks like a dairy multiple but the company is increasingly a platform play in functional nutrition. We …

Atour (ATAT) — Income Meets Growth in China's Lifestyle-Hotel Play

Atour (ATAT) — Income Meets Growth in China's Lifestyle-Hotel Play

Atour Lifestyle is building scale across hotels and retail experiences while returning cash to shareholders. With a $4.85B market cap, mid-30s valuation, and accelerating revenue growth, ATAT is a candidate for a long trade into a catalyst window (dividend, buybacks, travel recovery). The trade below balances upside to the 52-week highs with a defi…

MACOM IMS 2026 Product Announcements for Aerospace and Defense

MACOM IMS 2026 Product Announcements for Aerospace and Defense

MACOM Technology Solutions Inc. announced a new portfolio of high-performance RF solutions designed to meet stringent aerospace and defense requirements. These include high-power amplifiers and front-end modules across S-Band, C-Band, X-Band, and wideband frequencies, incorporating GaN and GaAs technologies to enhance radar, communications, and ele…

Xos announces $6 million common stock registered direct offering

Xos announces $6 million common stock registered direct offering

Xos, Inc., a US-based leader in electric commercial vehicles and energy storage systems, has announced a registered direct offering of approximately 1.1 million shares of common stock at $5.50 per share, intending to raise about $6 million in gross proceeds. The company plans to use the funds to expand its Power Hub and energy storage business targ…

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Emergent BioSolutions Inc. supports National Naloxone Awareness Day through partnership with Victoria's Voice Foundation to promote opioid overdose education and expand access to NARCAN® Nasal Spray and KLOXXADO® Nasal Spray. The company highlights new initiatives including the NARCAN® Nasal Spray Carrying Case and upcoming outreach in colleges to …

Weight Watchers to Increase Access to Comprehensive Weight Loss Options for Patients Nationwide through LillyDirect

Weight Watchers to Increase Access to Comprehensive Weight Loss Options for Patients Nationwide through LillyDirect

WW International, Inc. announces integration of its Weight Watchers Med+ program with Eli Lilly's digital healthcare platform, LillyDirect, to enhance nationwide patient access to GLP-1 prescription weight loss medications combined with behavioral and clinical support. This collaboration aims to provide a comprehensive and accessible approach to we…

Aya Gold & Silver Releases its 2025 Sustainability Report

Aya Gold & Silver Releases its 2025 Sustainability Report

Aya Gold & Silver Inc. released its 2025 Sustainability Report showcasing meaningful advancements in environmental management—such as reduced water and greenhouse gas intensities—robust social investments in local communities and employee training, and enhanced governance practices including ESG-linked executive incentives and increased female work…

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Inc. and Fountain Life announce the availability of cenplacel-L, a placental-derived allogeneic cell therapy, for investigational use by licensed physicians in Florida under recently enacted state legislation. This new regulatory framework allows use of certain cell therapies without FDA approval, enabling physician-directed application …

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

ARS Pharmaceuticals has announced a collaboration with former NFL star Drew Brees to raise awareness about severe food allergies and the importance of preparedness using neffy®, an FDA-approved needle-free epinephrine nasal spray. This partnership aims to educate patients and caregivers on prompt treatment of severe allergic reactions to prevent an…

ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy

ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy

ChronoScale Corporation announced the appointments of Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to accelerate the company's AI infrastructure platform growth and global compute solutions delivery. These leadership additions aim to strengthen innovation and scale operations to meet rising enterprise demand…

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

NextCure, Inc. announced the availability of a replay for its virtual Key Opinion Leader event discussing the first clinical efficacy data from the Phase 1 dose escalation study of SIM0505, an investigational antibody-drug conjugate targeting Cadherin-6, for ovarian and uterine serous carcinoma cancers. The event featured experts from leading cance…

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Amneal Pharmaceuticals announced FDA approval of its romidepsin injection solution, a ready-to-use formulation that simplifies hospital and pharmacy preparation compared to the previously marketed lyophilized powder. The product’s Competitive Generic Therapy designation grants Amneal 180 days of market exclusivity, enhancing its differentiated inje…

IMUNON Announces Up to $10 Million Cash Financing

IMUNON Announces Up to $10 Million Cash Financing

IMUNON, Inc. announced a structured financing deal raising up to $10 million to fund enrollment in its pivotal Phase 3 OVATION 3 trial of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The financing combines preferred stock issuance and secured promissory notes with favorable terms intended to minimize dilution. Recent Phase 2 …